China-based multinational Tencent and the UK’s Business Growth Fund (BGF) have joined an investor syndicate to provide new Series A funding to T-Therapeutics Ltd, a Cambridge University spin-out which is developing T cell receptor (TCR) T cell therapies. The latest funding, for $32 million, brings the total amount raised under the Series A round to $91 million. It will be used to advance the company’s prospective T cell receptor products to the clinic. The therapeutic focus is on cancer and autoimmune disease.
